Piper Sandler Upgrades CytomX Therapeutics to Overweight, Raises Price Target to $3.5
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler has upgraded CytomX Therapeutics (NASDAQ:CTMX) from Neutral to Overweight and raised the price target from $2.25 to $3.5, as per analyst Joseph Catanzaro.
May 28, 2024 | 9:27 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler has upgraded CytomX Therapeutics from Neutral to Overweight and raised the price target from $2.25 to $3.5.
The upgrade from Neutral to Overweight and the significant increase in the price target from $2.25 to $3.5 by a reputable analyst is likely to positively impact the stock price of CytomX Therapeutics in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100